Lunghi P - Search Results

1

McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Among authors: lunghi p. Expert Opin Emerg Drugs. 2010 Jun;15(2):203-23. doi: 10.1517/14728210903282760. Expert Opin Emerg Drugs. 2010. PMID: 20151845 Review.

2

MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors.

Bonati A, Lunghi P, Gammaitoni L, Pinelli S, Ridolo E, Dall'Aglio PP, Piacibello W, Aglietta M. Bonati A, et al. Among authors: lunghi p. Hematol J. 2002;3(2):105-13. doi: 10.1038/sj.thj.6200162. Hematol J. 2002. PMID: 12032872

3

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.

Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A. Giuliani N, et al. Among authors: lunghi p. Leukemia. 2004 Mar;18(3):628-35. doi: 10.1038/sj.leu.2403269. Leukemia. 2004. PMID: 14737074

4

Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.

Lunghi P, Costanzo A, Levrero M, Bonati A. Lunghi P, et al. Blood. 2004 Jul 15;104(2):519-25. doi: 10.1182/blood-2003-08-2743. Epub 2004 Mar 18. Blood. 2004. PMID: 15031205 Free article.

5

Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.

Lunghi P, Tabilio A, Lo-Coco F, Pelicci PG, Bonati A. Lunghi P, et al. Leukemia. 2005 Feb;19(2):234-44. doi: 10.1038/sj.leu.2403585. Leukemia. 2005. PMID: 15538402

6

Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.

Bonati A, Rizzoli V, Lunghi P. Bonati A, et al. Among authors: lunghi p. Curr Pharm Biotechnol. 2006 Dec;7(6):397-405. doi: 10.2174/138920106779116829. Curr Pharm Biotechnol. 2006. PMID: 17168655 Review.

7

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM. McCubrey JA, et al. Among authors: lunghi p. Leukemia. 2008 Apr;22(4):708-22. doi: 10.1038/leu.2008.27. Epub 2008 Mar 13. Leukemia. 2008. PMID: 18337766 Review.

8

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA. Steelman LS, et al. Among authors: lunghi p. Leukemia. 2008 Apr;22(4):686-707. doi: 10.1038/leu.2008.26. Epub 2008 Mar 13. Leukemia. 2008. PMID: 18337767 Review.

9

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS. McCubrey JA, et al. Among authors: lunghi p. Curr Opin Investig Drugs. 2008 Jun;9(6):614-30. Curr Opin Investig Drugs. 2008. PMID: 18516761

10

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.

Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, Testa U, Levrero M, Rizzoli V, Bonati A. Lunghi P, et al. Blood. 2008 Sep 15;112(6):2450-62. doi: 10.1182/blood-2007-10-114348. Epub 2008 Jun 26. Blood. 2008. PMID: 18583568 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page